Page Title
Clinical Trial Finder
Observational Completed with Results
TOBI Podhaler Usability Study (Novartis CTBM100C2412)
This study evaluated how well people were able to understand and follow the TOBI Podhaler® instructions for use to achieve appropriate dosing. Study participants were asked to inhale the contents of placebo capsules through the Podhaler device by following the instructions for use. Researchers evaluated if participants following the instructions demonstrated safe and effective use of the Podhaler device.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
25% or greater
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Previous experience with the Podhaler device.
Study Results
-
What We Learned:
This study showed that most participants can understand and follow the TOBI Podhaler instructions for use and can achieve safe and appropriate dosing.
-
Primary Findings:
Effectiveness:
Safety:
This study was conducted between August 2014 and February 2015 and enrolled 45 participants. All participants completed the study. The study found that most participants (78%; n=35/45) successfully followed the instructions to achieve safe and effective use of the device. The remaining 10 participants did not fully understand the instructions and therefore did not completely inhale the contents of the capsules, which resulted in an ineffective dose. The sponsor is considering modifying the instruction sheet to address these issues. No participants discontinued the study due to an adverse event. These data were provided by the Novartis Clinical Trial Results Website and have not been peer-reviewed.
-
Citation:
For current information about the overall development status of this drug, please check the Drug Development Pipeline.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
1 months -
Number of Study Visits:
2
Additional Information
-
Phase: ?more info
Phase Four/Post-Approval -
Study Sponsor: ?more info
Novartis -
Study Drugs:
N/A
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
25% or greater
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Previous experience with the Podhaler device.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More